Rekvina Laboratories Limited has announced the approval of its quarterly financial results for the third quarter of fiscal year 2026, marking another milestone in its regulatory compliance and corporate governance practices.

Board Meeting and Regulatory Compliance

The Board of Directors of Rekvina Laboratories Limited convened on February 6, 2026, to review and approve critical financial documents. The meeting details and outcomes are summarized below:

The board meeting was conducted pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, ensuring full compliance with regulatory requirements.

Financial Results Approval

During the board meeting, directors adopted and approved two key documents:

• Standalone Un-Audited Financial Results for the quarter and nine months ended December 31, 2025
• Limited Review Report by statutory auditors on the standalone unaudited financial results for the same period

The financial results were prepared in accordance with Indian Accounting Standard 34, Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act, 2013.

Auditor Review and Certification

Y. M. Shah & Co., Chartered Accountants, served as the statutory auditors and provided a limited review report on the financial results. The auditing firm, with registration number 114124W, conducted their review in accordance with Standard on Review Engagements (SRE) 2014.

The auditors confirmed that based on their review, nothing came to their attention that would suggest the financial statements were not prepared in accordance with applicable Indian Accounting Standards or contained material misstatements. The review was conducted to obtain moderate assurance regarding the accuracy of the financial information presented.

Company Information

Rekvina Laboratories Limited operates under CIN: L24231GJ1988PLC01145 with its registered office located at 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda. The company maintains its corporate communications through designated email addresses and contact numbers for stakeholder engagement.

Rekvina Laboratories Limited has informed the Bombay Stock Exchange about the resignation of its Non-Executive Independent Director Mr. Chetanbhai Jayantibhai Patel, effective January 29, 2026. The pharmaceutical company submitted the regulatory filing in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Resignation Details

Mr. Patel, who holds Director Identification Number (DIN) 06373484, tendered his resignation through a letter dated January 29, 2026. The resignation became effective from the close of business hours on the same date. Along with stepping down from his directorship, Mr. Patel has also resigned from his membership in various committees where he served as a member.

Regulatory Compliance

The company has fulfilled its disclosure obligations by providing comprehensive details as required under SEBI regulations. Company Secretary Deepak Khandelwal signed the regulatory filing, ensuring all necessary information was communicated to the stock exchange. The resignation letter explicitly states that there are no material reasons for the departure beyond the personal circumstances mentioned.

Corporate Impact

Mr. Patel's resignation affects the board composition of Rekvina Laboratories Limited, which is incorporated under CIN L24231GJ1988PLC01145. The company, headquartered in Baroda, Gujarat, operates in the pharmaceutical sector. The departing director also maintains business interests through his positions in Senpet Polymers LLP and Centurion Healthcare Pvt. Ltd.

The resignation follows standard corporate governance procedures, with the director expressing gratitude to the board and management for their support during his tenure. The company has requested the stock exchange to acknowledge receipt of the intimation and update their records accordingly.